LncRNAs expression signatures of hepatocellular carcinoma revealed by microarray

Table 1 Demographic and clinical characteristics of patients with hepatocellular carcinoma for the study of tissue lncRNAs expression n (%)

Parameters	Description	Minimum	Maximum
Age (yr)	56.59 ± 10.97	30	73
Gender
Male	26 (89.70)
Female	3 (10.30)
Hepatitis virus infection
HBV	22 (75.90)
HCV	3 (10.30)
Negative	4 (13.80)
Tumor size (cm)	6.44 ± 3.65	2	19
Tumor differentiation
Well	6 (20.70)
Moderate	16 (55.20)
Poor	7 (24.10)
TNM stage
I	10 (34.50)
II	11 (37.90)
III	7 (14.0)
IV	1 (3.40)
BCLC stage
A	21 (72.40)
B	1 (3.40)
C	7 (24.10)
AFP (ng/mL)
≤ 400	17 (58.60)
> 400	12 (41.40)
PVTT
Present	23 (79.30)
Absent	6 (20.70)
Tumor number
Single	27 (93.10)
Multiple	2 (6.90)
Capsule invasive
Present	6 (20.70)
Absent	23 (79.30)
ALP (U/L)	42.90 ± 32.24	11	159
ALB (g/L)	39.86 ± 3.72	28	47
TBIL (μmol/L)	15.36 ± 7.41	7.1	42.6
DBIL (μmol/L)	6.10 ± 3.08	3	16.5

Data are expressed as mean ± SD or n (%). TNM: Tumor-node-metastasis staging system; BCLC: The Barcelona Clinic Liver Cancer staging system; HBV: Hepatitis B virus; HCV: Hepatitis C virus; AFP: Alpha fetoprotein; PVTT: Portal vein tumor thrombus; ALP: Alkaline phosphatase; ALB: Albumin; TBIL: Total bilirubin; DBIL: Direct bilirubin.